A bone marrow transplant process co-developed by investigators at the Johns Hopkins Kimmel Cancer Center is safe and curative ...
Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
The Omaha resident, who has adopted and fostered a number of dogs, had traveled to the shelter hoping to adopt a Japanese ...
Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...
US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
The global Cell and Gene Therapy Market is valued at $20.5 billion in 2024 and is projected to reach a value of $128.8 ...
Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
The Franklin County Board of Commissioners has passed a resolution urging the Benton Franklin Health District (BFHD) to cease ...
US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback